Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDProtagonist Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 6 | -$1.03 | $0.33 | -$0.06 |
| Q2 2025 | 3 | -$0.57 | -$0.57 | -$0.57 |
| Q3 2025 | 3 | -$0.56 | -$0.56 | -$0.56 |
| Q4 2025 | 3 | -$0.16 | -$0.16 | -$0.16 |
| Q1 2026 | 3 | -$0.42 | -$0.42 | -$0.42 |
| Q2 2026 | 3 | -$0.57 | -$0.57 | -$0.57 |
| Q3 2026 | 3 | -$0.60 | -$0.60 | -$0.60 |
| Q4 2026 | 3 | -$0.32 | -$0.32 | -$0.32 |
Protagonist Therapeutics, Inc. Earnings Date And Information
Protagonist Therapeutics, Inc. last posted its earnings results on Friday, February 21st, 2025. The company reported $1.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $1.92. The company had revenue of 170.64 M for the quarter and had revenue of 434.43 M for the year. Protagonist Therapeutics, Inc. has generated $4 earnings per share over the last year ($4.23 diluted earnings per share) and currently has a price-to-earnings ratio of 12.9. Protagonist Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based on prior year's report dates.
Protagonist Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/21/2025 | Q4 2024 | $0.06 | $2.14 | 2.08 | $132.36 M | $170.64 M |
| 11/07/2024 | Q3 2024 | -$0.59 | -$0.54 | 0.05 | $3.11 M | $4.68 M |
| 08/06/2024 | Q2 2024 | -$0.50 | -$0.50 | 0 | $3.14 M | $4.17 M |
| 05/07/2024 | Q1 2024 | $1.19 | $3.41 | 2.22 | N/A | $254.95 M |
| 02/27/2024 | Q4 2023 | $0.03 | $0.45 | 0.42 | $60.00 M | $60.00 M |
| 11/02/2023 | Q3 2023 | -$0.68 | -$0.58 | 0.1 | N/A | $0 |
| 08/03/2023 | Q2 2023 | -$0.65 | -$0.68 | -0.03 | N/A | $0 |
| 05/04/2023 | Q1 2023 | -$0.69 | -$0.62 | 0.07 | N/A | $0 |
| 03/15/2023 | Q4 2022 | -$0.67 | -$0.64 | 0.03 | N/A | $0 |
| 11/08/2022 | Q3 2022 | -$0.94 | -$0.62 | 0.32 | N/A | $0 |
| 08/04/2022 | Q2 2022 | -$0.99 | -$0.83 | 0.16 | $460,000 | $859,000 |
| 05/05/2022 | Q1 2022 | N/A | -$0.43 | N/A | N/A | $25.72 M |
| 02/28/2022 | Q4 2021 | -$0.79 | -$0.77 | 0.02 | N/A | $8.62 M |
| 11/03/2021 | Q3 2021 | -$0.67 | -$0.70 | -0.03 | $1.74 M | $10.29 M |
| 08/04/2021 | Q2 2021 | -$0.62 | -$0.69 | -0.07 | $5.17 M | $2.27 M |
| 05/04/2021 | Q1 2021 | -$0.57 | -$0.54 | 0.03 | N/A | $6.19 M |
| 03/10/2021 | Q4 2020 | -$0.47 | -$0.48 | -0.01 | N/A | $5.65 M |
| 11/04/2020 | Q3 2020 | -$0.61 | -$0.21 | 0.4 | $2.87 M | $13.11 M |
| 08/06/2020 | Q2 2020 | -$0.57 | -$0.59 | -0.02 | $2.95 M | $6.22 M |
| 05/07/2020 | Q1 2020 | -$0.64 | -$0.72 | -0.08 | N/A | $3.65 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Protagonist Therapeutics, Inc. Earnings: FAQ's
Protagonist Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based offlast year's report dates.
In the previous quarter, Protagonist Therapeutics, Inc. (:PTGX) reported $1.98 earnings per share (EPS) to beat the analysts' consensus estimate of $0.06 by $1.92.
The conference call for Protagonist Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Protagonist Therapeutics, Inc.'s latest earnings report can be read online.
Protagonist Therapeutics, Inc. (:PTGX) has a recorded annual revenue of $434.43 M.
Protagonist Therapeutics, Inc. (:PTGX) has a recorded net income of $275.19 M.Protagonist Therapeutics, Inc. has generated $4.47 earnings per share over the last four quarters.
Protagonist Therapeutics, Inc. (:PTGX) has a price-to-earnings ratio of 12.9 and price/earnings-to-growth ratio is 0.22.